Table 4.
Treatment characteristics according to ALBI score at baseline
| Overall (n = 205) | ALBI 1 (n = 70) | ALBI 2 (n = 116) | ALBI 3 (n = 19) | |
|---|---|---|---|---|
| Best response under lenvatinib treatment | ||||
| Complete response | 1 (0.4) | 0 | 1 (0.9) | 0 |
| Partial response | 47 (22.9) | 22 (31.4) | 21 (18.2) | 4 (21.1) |
| Stable disease | 69 (33.7) | 27 (38.6) | 36 (31.0) | 6 (31.6) |
| Progressive disease | 43 (20.9) | 14 (20.0) | 23 (19.8) | 6 (31.6) |
| End of treatment before first imaging | 38 (18.6) | 3 (4.3) | 33 (28.4) | 2 (10.5) |
| No data available | 7 (3.5) | 4 (5.7) | 2 (1.7) | 1 (5.2) |
| Median overall survival, months | 12.8 | 19.9 | 11.2 | 7.1 |
| Median progression-free survival, months | 6.4 | 8.6 | 5.9 | 4.9 |
| Disease control | 117 (57.1) | 49 (70) | 58 (50.0) | 10 (52.5) |
| Overall response | 48 (23.4) | 22 (31.4) | 22 (19.0) | 4 (21.1) |
| AFP reduction >20% under treatment | 57 (27.8) | 22 (31.4) | 31 (26.7) | 4 (21.1) |
| Reason for end of treatment | ||||
| Progression | 93 (45.5) | 39 (55.8) | 43 (37.2) | 11 (57.9) |
| Adverse events | 75 (36.5) | 16 (22.8) | 52 (44.8) | 7 (36.8) |
| Liver function deterioration | 30 (14.6) | 5 (7.1) | 21 (18.1) | 4 (21.0) |
| Other adverse events | 45 (21.9) | 11 (15.7) | 31 (26.7) | 3 (15.8) |
| Patient choice | 3 (1.4) | 1 (1.4) | 2 (1.7) | 0 |
| Others | 4 (2.0) | 1 (1.4) | 3 (2.6) | 0 |
| No data available | 6 (2.9) | 3 (4.2) | 3 (2.6) | 0 |
| Treatment ongoing | 24 (11.7) | 11 (15.7) | 12 (10.3) | 1 (5.2) |
Lenvatinib treatment characteristics according to ALBI score at baseline.